Abstract Library

#3952 Peptide Receptor Radionuclide Therapy (PRRT) in the management of patients with ectopic Cushing’s syndrome due to metastatic gastroenteropancreatic neuroendocrine neoplasia (GEPNEN): A single centre experience

Introduction: Metastatic GEPNEN can cause ectopic Cushing’s syndrome (ECS). ECS is highly morbid and often refractory to medical therapy. Bilateral adrenalectomy (BA) carries risk and long-term morbidity. Patients (pts) unsuitable for surgery have dismal outcomes. Peptide receptor radionuclide therapy (PRRT) is a rational option for hormone control in ECS caused by NEN with high somatostatin receptor (SSTR) expression yet detailed case series to guide its use are lacking.

Conference:

Presenting Author: Boehm E

Authors: Boehm E, Hung T, Akhurst T, Alipour R, Cardin A,

Keywords: GEPNEN, PRRT, Ectopic Cushing's Syndrome,

#3310 Ectopic Cushing’s syndrome: Experience from a tertiary care center

Introduction: Neuroendocrine neoplasms (NENs) causing ectopic Cushing’s syndrome (ECS) are relatively rare and very challenging to treat.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lase I

Authors: Lase I, Grönberg M, Strele I, Kozlovacki G, Norlën O,

Keywords: Ectopic Cushing’s syndrome, ACTH, neuroendocrine, hypercortisolism, multiple hormone secretion, bilateral adrenalectomy,

#1206 Two Cases of Ectopic ACTH-Secreting Neoplasm of Occult Origin Becoming Overt After Bilateral Adrenalectomy

Introduction: Cushing's syndrome (CS) is an endocrine disorder associated with serious consequences if not adequately treated. Nearly 80% of the cases of endogenous hypercortisolism are adrenocorticotropic hormone (ACTH) dependent, the ACTH source being pituitary in about 70-80% and ectopic in 10-15%. The ACTH source may remain occult in few cases for many years in spite of extensive investigations.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Piacentini S, Iacovazzo D, Lugli F, Giampietro A, Bianchi A,

Keywords: Cushing's syndrome, Ectopic ACTH, Bilateral adrenalectomy,

#858 Metastatic Pancreatic Neuroendocrine Tumors with Ectopic Cushing Syndrome: Could Everolimus Be a Safe Therapeutic Option?

Introduction: Everolimus(E) has proved effective in prolonging PFS in advanced P-NETs. As E is a substrate of CYP3A4 co-administration with ketoconazole (k), a strong inhibitor of CYP3A4 used to control hypercortisolism, should be avoided.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: davi' m

Authors: Davì M, Cingarlini S, Butturini G, Capelli P, Scarpa A,

Keywords: Everolimus, pancreatic NET, ectopic Cushing syndrome,